glp 1 non injectable Non-insulin antidiabetic drugs - GLP-1 agonists and amylinomimetics Non-insulin injectable medicines - International
Description
The first incretin approved by the FDA in May 2005 was Byetta (exenatide)
For others, side effects can interfere with daily life
Diabetes Type Specificity: While semaglutide is effective for type 2 diabetes, it is not suitable for type 1 diabetes management
Its not a commitment
